53
EVALUATION DIGITALER THERAPEUTIKA NEUE STUDIENDESIGNS UND REAL WORLD EVIDENCE Lars G. Hemkens Heidelberg, 27. Februar 2020 web version

EVALUATION DIGITALER THERAPEUTIKA€¦ · R Salman (U Edinburgh) H Ewald (U Basel) KA Mc Cord (U Basel) M Briel (U Basel) C Pauli-Magnus (U Basel) HM Verkoijen (U Utrecht) U Dirnagl

  • Upload
    others

  • View
    2

  • Download
    0

Embed Size (px)

Citation preview

Page 1: EVALUATION DIGITALER THERAPEUTIKA€¦ · R Salman (U Edinburgh) H Ewald (U Basel) KA Mc Cord (U Basel) M Briel (U Basel) C Pauli-Magnus (U Basel) HM Verkoijen (U Utrecht) U Dirnagl

EVALUATION DIGITALER THERAPEUTIKA

NEUE STUDIENDESIGNS UND REAL WORLD EVIDENCE

Lars G. Hemkens

Heidelberg, 27. Februar 2020

web version

Page 2: EVALUATION DIGITALER THERAPEUTIKA€¦ · R Salman (U Edinburgh) H Ewald (U Basel) KA Mc Cord (U Basel) M Briel (U Basel) C Pauli-Magnus (U Basel) HM Verkoijen (U Utrecht) U Dirnagl

University of Basel, Department of Clinical Research

Page 3: EVALUATION DIGITALER THERAPEUTIKA€¦ · R Salman (U Edinburgh) H Ewald (U Basel) KA Mc Cord (U Basel) M Briel (U Basel) C Pauli-Magnus (U Basel) HM Verkoijen (U Utrecht) U Dirnagl

“Women havefewer teeth thanmen“

Aristoteles; HA II 3, 501b19

Page 4: EVALUATION DIGITALER THERAPEUTIKA€¦ · R Salman (U Edinburgh) H Ewald (U Basel) KA Mc Cord (U Basel) M Briel (U Basel) C Pauli-Magnus (U Basel) HM Verkoijen (U Utrecht) U Dirnagl

“Pneumonia is one ofthe diseases in whicha timely venesection

may save life“

Sir William Osler; Principles and Practice of Medicine;1892

Page 5: EVALUATION DIGITALER THERAPEUTIKA€¦ · R Salman (U Edinburgh) H Ewald (U Basel) KA Mc Cord (U Basel) M Briel (U Basel) C Pauli-Magnus (U Basel) HM Verkoijen (U Utrecht) U Dirnagl

Bloodletting for pneumonia

Mercury for syphilis

Lobotomy for psychiatric diseases

Heroin for cough

Bedrest in myocardial infarction

Low-fiber diet in diverticulosis

Babys sleep on stomach

Surgery for peptic ulcers

Intensive glucose lowering in type 2 diabetes

Hormone replacement therapy in women

Vitamine E in cardiac diseases

Antiarrhythmic in myocardial infarction

Stents in stable CVD

Page 6: EVALUATION DIGITALER THERAPEUTIKA€¦ · R Salman (U Edinburgh) H Ewald (U Basel) KA Mc Cord (U Basel) M Briel (U Basel) C Pauli-Magnus (U Basel) HM Verkoijen (U Utrecht) U Dirnagl

„Approximately 90% of new drugs entered into clinical development on

promising preclinical findings

fail to yield sufficient efficacy and

safety to receive …(FDA) license“

Benjamin et al. PLoS Biol 2017 (citing Hay et al. Nature Biotech 2014; 32: 40-51).

)

Page 7: EVALUATION DIGITALER THERAPEUTIKA€¦ · R Salman (U Edinburgh) H Ewald (U Basel) KA Mc Cord (U Basel) M Briel (U Basel) C Pauli-Magnus (U Basel) HM Verkoijen (U Utrecht) U Dirnagl
Page 8: EVALUATION DIGITALER THERAPEUTIKA€¦ · R Salman (U Edinburgh) H Ewald (U Basel) KA Mc Cord (U Basel) M Briel (U Basel) C Pauli-Magnus (U Basel) HM Verkoijen (U Utrecht) U Dirnagl

BIG DATAROUTINELY COLLECTED DATA

Page 9: EVALUATION DIGITALER THERAPEUTIKA€¦ · R Salman (U Edinburgh) H Ewald (U Basel) KA Mc Cord (U Basel) M Briel (U Basel) C Pauli-Magnus (U Basel) HM Verkoijen (U Utrecht) U Dirnagl

Insurance data / claims data

Electronic Health Records

Registries

Microsoft

Bing

Google

Twitter

Amazon

Facebook

Whatsapp

Netflix

LinkedIn

Wearables

Fitbit

Firefox

IoT (Internet of Things)

Page 10: EVALUATION DIGITALER THERAPEUTIKA€¦ · R Salman (U Edinburgh) H Ewald (U Basel) KA Mc Cord (U Basel) M Briel (U Basel) C Pauli-Magnus (U Basel) HM Verkoijen (U Utrecht) U Dirnagl

Real World Data

“Real-world data are the data relating to patient health status and/or the delivery of health care routinely collected from a variety of sources. RWD can come from a number of sources, for example:

Electronic health records (EHRs)

Claims and billing activities

Product and disease registries

Patient-generated data including in home-use settings

Data gathered from other sources that can inform on health status, such as mobile devices”

www.fda.gov/science-research/science-and-research-special-topics/real-world-evidence

Accessed 23 Sep 2019

Page 11: EVALUATION DIGITALER THERAPEUTIKA€¦ · R Salman (U Edinburgh) H Ewald (U Basel) KA Mc Cord (U Basel) M Briel (U Basel) C Pauli-Magnus (U Basel) HM Verkoijen (U Utrecht) U Dirnagl

"Data collection under real-world circumstances maximizes representativeness and generalizability, minimizes costs and effort, and allows the capture of information in large populations and many clinical events in large data sets that are continuously updated and cover long periods."

Hemkens et al. CMAJ 2016

Page 12: EVALUATION DIGITALER THERAPEUTIKA€¦ · R Salman (U Edinburgh) H Ewald (U Basel) KA Mc Cord (U Basel) M Briel (U Basel) C Pauli-Magnus (U Basel) HM Verkoijen (U Utrecht) U Dirnagl

Safeguards of clinical trial research often lacking

Protocols

Registration

Research networks

Prospective Analysis

...

Page 13: EVALUATION DIGITALER THERAPEUTIKA€¦ · R Salman (U Edinburgh) H Ewald (U Basel) KA Mc Cord (U Basel) M Briel (U Basel) C Pauli-Magnus (U Basel) HM Verkoijen (U Utrecht) U Dirnagl
Page 14: EVALUATION DIGITALER THERAPEUTIKA€¦ · R Salman (U Edinburgh) H Ewald (U Basel) KA Mc Cord (U Basel) M Briel (U Basel) C Pauli-Magnus (U Basel) HM Verkoijen (U Utrecht) U Dirnagl

CONFOUNDING

Page 15: EVALUATION DIGITALER THERAPEUTIKA€¦ · R Salman (U Edinburgh) H Ewald (U Basel) KA Mc Cord (U Basel) M Briel (U Basel) C Pauli-Magnus (U Basel) HM Verkoijen (U Utrecht) U Dirnagl

From http://tylervigen.com/view_correlation?id=28807

Thanks to Tyler Vigen for sharing (accessed 22 February 2020)

Page 16: EVALUATION DIGITALER THERAPEUTIKA€¦ · R Salman (U Edinburgh) H Ewald (U Basel) KA Mc Cord (U Basel) M Briel (U Basel) C Pauli-Magnus (U Basel) HM Verkoijen (U Utrecht) U Dirnagl

From http://tylervigen.com/view_correlation?id=28672

Thanks to Tyler Vigen for sharing (accessed 22 February 2020)

Page 17: EVALUATION DIGITALER THERAPEUTIKA€¦ · R Salman (U Edinburgh) H Ewald (U Basel) KA Mc Cord (U Basel) M Briel (U Basel) C Pauli-Magnus (U Basel) HM Verkoijen (U Utrecht) U Dirnagl

From http://tylervigen.com/view_correlation?id=28669

Thanks to Tyler Vigen for sharing (accessed 22 February 2020)

Page 18: EVALUATION DIGITALER THERAPEUTIKA€¦ · R Salman (U Edinburgh) H Ewald (U Basel) KA Mc Cord (U Basel) M Briel (U Basel) C Pauli-Magnus (U Basel) HM Verkoijen (U Utrecht) U Dirnagl

From http://tylervigen.com/view_correlation?id=28829

Thanks to Tyler Vigen for sharing (accessed 22 February 2020)

Page 19: EVALUATION DIGITALER THERAPEUTIKA€¦ · R Salman (U Edinburgh) H Ewald (U Basel) KA Mc Cord (U Basel) M Briel (U Basel) C Pauli-Magnus (U Basel) HM Verkoijen (U Utrecht) U Dirnagl

Nationwide Big Data

From www.tylervigen.com/spurious-correlations

Thanks to Tyler Vigen for sharing (accessed 8 March 2017)

Page 20: EVALUATION DIGITALER THERAPEUTIKA€¦ · R Salman (U Edinburgh) H Ewald (U Basel) KA Mc Cord (U Basel) M Briel (U Basel) C Pauli-Magnus (U Basel) HM Verkoijen (U Utrecht) U Dirnagl

Nationwide Big Data

From www.tylervigen.com/spurious-correlations

Thanks to Tyler Vigen for sharing (accessed 8 March 2017)

Page 21: EVALUATION DIGITALER THERAPEUTIKA€¦ · R Salman (U Edinburgh) H Ewald (U Basel) KA Mc Cord (U Basel) M Briel (U Basel) C Pauli-Magnus (U Basel) HM Verkoijen (U Utrecht) U Dirnagl

Byberg et al. Clinical and Translational Allergy 2016;6:33; Figure S1

URL: https://ctajournal.biomedcentral.com/articles/10.1186/s13601-016-0124-9

CC-BY 4.0: http://creativecommons.org/licenses/by/4.0/ No changes were made

Some Confounder RelationshipsBMI and physical activity in early childhood with atopy

Paternal factors?Ethnicity?Resp. infections?Socioeconomics?Patient preferences and values?

Page 22: EVALUATION DIGITALER THERAPEUTIKA€¦ · R Salman (U Edinburgh) H Ewald (U Basel) KA Mc Cord (U Basel) M Briel (U Basel) C Pauli-Magnus (U Basel) HM Verkoijen (U Utrecht) U Dirnagl

Wallach et al. (PrePrint/under review)www.researchsquare.com/article/8e138689-12d5-43fa-87c9-9766d9e11a53/v1

Some Confounder RelationshipsAlcohol and Cardiovascular disease

Page 23: EVALUATION DIGITALER THERAPEUTIKA€¦ · R Salman (U Edinburgh) H Ewald (U Basel) KA Mc Cord (U Basel) M Briel (U Basel) C Pauli-Magnus (U Basel) HM Verkoijen (U Utrecht) U Dirnagl

Chu et al. Int J Epidemiol. 2020

97 studies:

Pickyour

effect

Page 24: EVALUATION DIGITALER THERAPEUTIKA€¦ · R Salman (U Edinburgh) H Ewald (U Basel) KA Mc Cord (U Basel) M Briel (U Basel) C Pauli-Magnus (U Basel) HM Verkoijen (U Utrecht) U Dirnagl
Page 25: EVALUATION DIGITALER THERAPEUTIKA€¦ · R Salman (U Edinburgh) H Ewald (U Basel) KA Mc Cord (U Basel) M Briel (U Basel) C Pauli-Magnus (U Basel) HM Verkoijen (U Utrecht) U Dirnagl

Ioannidis JAMA 2005

"Five of 6 highly-cited nonrandomized studies had been contradicted or had found stronger effects vs 9 of 39 randomized controlled trials (P = .008)."

Page 26: EVALUATION DIGITALER THERAPEUTIKA€¦ · R Salman (U Edinburgh) H Ewald (U Basel) KA Mc Cord (U Basel) M Briel (U Basel) C Pauli-Magnus (U Basel) HM Verkoijen (U Utrecht) U Dirnagl

16 clinical questions / 16 RCD studies

36 subsequent RCTs

17 275 patients

835 deaths

Propensity Scores

Mortality

Hemkens et al. BMJ 2016;352:i493

URL: http://www.bmj.com/content/bmj/352/bmj.i493.full.pdf

CC-BY 4.0: http://creativecommons.org/licenses/by/4.0/ No changes were made

Page 27: EVALUATION DIGITALER THERAPEUTIKA€¦ · R Salman (U Edinburgh) H Ewald (U Basel) KA Mc Cord (U Basel) M Briel (U Basel) C Pauli-Magnus (U Basel) HM Verkoijen (U Utrecht) U Dirnagl

RCD studies find 31% larger benefits than later RCTs(ROR 1.31)

In various re-analyses ROR from 1.25 to 1.58

Hemkens et al. BMJ 2016;352:i493

URL: http://www.bmj.com/content/bmj/352/bmj.i493.full.pdf

CC-BY 4.0: http://creativecommons.org/licenses/by/4.0/ No changes were made

Page 28: EVALUATION DIGITALER THERAPEUTIKA€¦ · R Salman (U Edinburgh) H Ewald (U Basel) KA Mc Cord (U Basel) M Briel (U Basel) C Pauli-Magnus (U Basel) HM Verkoijen (U Utrecht) U Dirnagl

“Big Data presents manyexciting new opportunities, but there is no underlyingrevolution in the logic of howclaims about the effects oftreatment should be justified.” S Goodman, S Schneeweiss, M Baiocchi JAMA 2017

JAMA 2017

Page 29: EVALUATION DIGITALER THERAPEUTIKA€¦ · R Salman (U Edinburgh) H Ewald (U Basel) KA Mc Cord (U Basel) M Briel (U Basel) C Pauli-Magnus (U Basel) HM Verkoijen (U Utrecht) U Dirnagl

Page 30: EVALUATION DIGITALER THERAPEUTIKA€¦ · R Salman (U Edinburgh) H Ewald (U Basel) KA Mc Cord (U Basel) M Briel (U Basel) C Pauli-Magnus (U Basel) HM Verkoijen (U Utrecht) U Dirnagl

Non-Randomized

vs.

Randomized

RCD Active

Page 31: EVALUATION DIGITALER THERAPEUTIKA€¦ · R Salman (U Edinburgh) H Ewald (U Basel) KA Mc Cord (U Basel) M Briel (U Basel) C Pauli-Magnus (U Basel) HM Verkoijen (U Utrecht) U Dirnagl

Learning from Winners

Page 32: EVALUATION DIGITALER THERAPEUTIKA€¦ · R Salman (U Edinburgh) H Ewald (U Basel) KA Mc Cord (U Basel) M Briel (U Basel) C Pauli-Magnus (U Basel) HM Verkoijen (U Utrecht) U Dirnagl

41 SHADES OF BLUE

Page 33: EVALUATION DIGITALER THERAPEUTIKA€¦ · R Salman (U Edinburgh) H Ewald (U Basel) KA Mc Cord (U Basel) M Briel (U Basel) C Pauli-Magnus (U Basel) HM Verkoijen (U Utrecht) U Dirnagl

„..a team at Google

couldn’t decide between two blues,

so they’re testing

41 shades between each blue

to see which one performs better...

I can’t operate in an environment like that.“

Douglas Bowman, Google’s previous visual design leader left Google

https://stopdesign.com/archive/2009/03/20/goodbye-google.html

Page 34: EVALUATION DIGITALER THERAPEUTIKA€¦ · R Salman (U Edinburgh) H Ewald (U Basel) KA Mc Cord (U Basel) M Briel (U Basel) C Pauli-Magnus (U Basel) HM Verkoijen (U Utrecht) U Dirnagl

Today,

Microsoft and several other leading companies

including Amazon, Booking.com, Facebook, and Google each conduct

more than 10000 online controlled experiments

annually…

Kohavi R, Thomke HS. Havard Buisness Review 2017

Page 35: EVALUATION DIGITALER THERAPEUTIKA€¦ · R Salman (U Edinburgh) H Ewald (U Basel) KA Mc Cord (U Basel) M Briel (U Basel) C Pauli-Magnus (U Basel) HM Verkoijen (U Utrecht) U Dirnagl

„The idea increased

Bing’s revenue by 12%(over $120M at the time)“

R. Kohavihttp://bit.ly/2017ABTestingTutorial

Page 36: EVALUATION DIGITALER THERAPEUTIKA€¦ · R Salman (U Edinburgh) H Ewald (U Basel) KA Mc Cord (U Basel) M Briel (U Basel) C Pauli-Magnus (U Basel) HM Verkoijen (U Utrecht) U Dirnagl

“Only one third of the ideas tested at Microsoft

improved the metric(s) they

were designed to improve”

Kohavi, R. et al. 2013 Online Controlled Experiments at Large Scale.

Retrieved from http://bit.ly/ExPScale

Page 37: EVALUATION DIGITALER THERAPEUTIKA€¦ · R Salman (U Edinburgh) H Ewald (U Basel) KA Mc Cord (U Basel) M Briel (U Basel) C Pauli-Magnus (U Basel) HM Verkoijen (U Utrecht) U Dirnagl

Kohavi et al. Trials 2020;21:150

URL: https://trialsjournal.biomedcentral.com/track/pdf/10.1186/s13063-020-4084-y

CC-BY 4.0: http://creativecommons.org/licenses/by/4.0/ No changes were made

Page 38: EVALUATION DIGITALER THERAPEUTIKA€¦ · R Salman (U Edinburgh) H Ewald (U Basel) KA Mc Cord (U Basel) M Briel (U Basel) C Pauli-Magnus (U Basel) HM Verkoijen (U Utrecht) U Dirnagl

Kohavi et al. Trials 2020;21:150

URL: https://trialsjournal.biomedcentral.com/track/pdf/10.1186/s13063-020-4084-y

CC-BY 4.0: http://creativecommons.org/licenses/by/4.0/ No changes were made

Page 39: EVALUATION DIGITALER THERAPEUTIKA€¦ · R Salman (U Edinburgh) H Ewald (U Basel) KA Mc Cord (U Basel) M Briel (U Basel) C Pauli-Magnus (U Basel) HM Verkoijen (U Utrecht) U Dirnagl

Learning Health Care System

Page 40: EVALUATION DIGITALER THERAPEUTIKA€¦ · R Salman (U Edinburgh) H Ewald (U Basel) KA Mc Cord (U Basel) M Briel (U Basel) C Pauli-Magnus (U Basel) HM Verkoijen (U Utrecht) U Dirnagl

RCD for RCT

Page 41: EVALUATION DIGITALER THERAPEUTIKA€¦ · R Salman (U Edinburgh) H Ewald (U Basel) KA Mc Cord (U Basel) M Briel (U Basel) C Pauli-Magnus (U Basel) HM Verkoijen (U Utrecht) U Dirnagl

RCD for RCTIdentification/recruitment Screen EHR-database for eligible

patients Inform Study design Power Calculation/ Feasibility

Send recruitment message

Page 42: EVALUATION DIGITALER THERAPEUTIKA€¦ · R Salman (U Edinburgh) H Ewald (U Basel) KA Mc Cord (U Basel) M Briel (U Basel) C Pauli-Magnus (U Basel) HM Verkoijen (U Utrecht) U Dirnagl

RCD for RCTExtended follow-up Long-term outcomes Expanding previous trials

(Registry Linkage)

Page 43: EVALUATION DIGITALER THERAPEUTIKA€¦ · R Salman (U Edinburgh) H Ewald (U Basel) KA Mc Cord (U Basel) M Briel (U Basel) C Pauli-Magnus (U Basel) HM Verkoijen (U Utrecht) U Dirnagl

RCD for RCTOutcome Assessment Length of hospital stay Adverse events Complications ICU stay Re-admission Ressource use / Costs

Many of the most patient-relevant outcomes!

Page 44: EVALUATION DIGITALER THERAPEUTIKA€¦ · R Salman (U Edinburgh) H Ewald (U Basel) KA Mc Cord (U Basel) M Briel (U Basel) C Pauli-Magnus (U Basel) HM Verkoijen (U Utrecht) U Dirnagl

RCD for RCTIntervention EHR-based diagnostic support

tools (e.g. AI, algorithms) Alert systems Prescription feedback

Learning healthcare system

Page 45: EVALUATION DIGITALER THERAPEUTIKA€¦ · R Salman (U Edinburgh) H Ewald (U Basel) KA Mc Cord (U Basel) M Briel (U Basel) C Pauli-Magnus (U Basel) HM Verkoijen (U Utrecht) U Dirnagl

Mc Cord et al. CMAJ Open 2019https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6375253/pdf/cmajo.20180096.pdf

RCD for RCT – Kosten

Page 46: EVALUATION DIGITALER THERAPEUTIKA€¦ · R Salman (U Edinburgh) H Ewald (U Basel) KA Mc Cord (U Basel) M Briel (U Basel) C Pauli-Magnus (U Basel) HM Verkoijen (U Utrecht) U Dirnagl

Schnelle AntwortenGlaubwürdige Evidenz

Geringe Kosten

Page 47: EVALUATION DIGITALER THERAPEUTIKA€¦ · R Salman (U Edinburgh) H Ewald (U Basel) KA Mc Cord (U Basel) M Briel (U Basel) C Pauli-Magnus (U Basel) HM Verkoijen (U Utrecht) U Dirnagl

???

Späte AntwortenGlaubwürdige Evidenz

Hohe Kosten

Randomisierte Studien

Page 48: EVALUATION DIGITALER THERAPEUTIKA€¦ · R Salman (U Edinburgh) H Ewald (U Basel) KA Mc Cord (U Basel) M Briel (U Basel) C Pauli-Magnus (U Basel) HM Verkoijen (U Utrecht) U Dirnagl

The Magic of Randomization

Page 49: EVALUATION DIGITALER THERAPEUTIKA€¦ · R Salman (U Edinburgh) H Ewald (U Basel) KA Mc Cord (U Basel) M Briel (U Basel) C Pauli-Magnus (U Basel) HM Verkoijen (U Utrecht) U Dirnagl

WHY NOT ???MODELLIERUNG RANDOMISIERUNG

Datenmenge deutlich mehr

Datenqualität höhere Anforderung

Statistische Modelle komplexer

Annahmen / Verständnis Wirkprinzip komplexer

Risiko für Fehler/Bias deutlich höher

Einverständnis erforderlich

Kosten eher höher

Vorteil Modellierung Vorteil Randomisierung

IMMER: Registrierung, Studienprotokoll, Analyseplan, Ethikvotum, Follow-up, Publikationen…

Page 50: EVALUATION DIGITALER THERAPEUTIKA€¦ · R Salman (U Edinburgh) H Ewald (U Basel) KA Mc Cord (U Basel) M Briel (U Basel) C Pauli-Magnus (U Basel) HM Verkoijen (U Utrecht) U Dirnagl

“Obstacles to randomized trials

should be removed to protectpatients…

Promotion of nonrandomized analyses

… is a false solution to the problems

caused by the bureaucratic burdensimposed on … trials...” R Collins, L Bowman, M Landray, R Peto, NEJM 2020

“The Magic of Randomization versus the Myth of Real-World Evidence” NEJM 382;7 February 13, 2020

Page 51: EVALUATION DIGITALER THERAPEUTIKA€¦ · R Salman (U Edinburgh) H Ewald (U Basel) KA Mc Cord (U Basel) M Briel (U Basel) C Pauli-Magnus (U Basel) HM Verkoijen (U Utrecht) U Dirnagl

“Sometimes when you innovate, you make mistakes.

It is best to admit them quickly, and get on with improving your

other innovations“

Steve Jobs

Page 52: EVALUATION DIGITALER THERAPEUTIKA€¦ · R Salman (U Edinburgh) H Ewald (U Basel) KA Mc Cord (U Basel) M Briel (U Basel) C Pauli-Magnus (U Basel) HM Verkoijen (U Utrecht) U Dirnagl

JPA Ioannidis (U Stanford)

D Contopoulus-Ioannidis (U Stanford)

R Salman (U Edinburgh)

H Ewald (U Basel)

KA Mc Cord (U Basel)

M Briel (U Basel)

C Pauli-Magnus (U Basel)

HM Verkoijen (U Utrecht)

U Dirnagl (Charite / BIH / QUEST)

B Kasenda (iomedico/U Basel)

TV Pereira (U Toronto)

F Naudet (METRICS / INSERM)

O Fröbert (U Orebro)

B Speich (U Oxford)

R Kohavi (Microsoft/Airbnb)

Special Thanks

[email protected]

@LGHemkens

PD Dr. med. Lars G. Hemkens MPHDepartment of Clinical ResearchUniversity Hospital Basel Switzerland

QUEST (Quality | Ethics | Open Science | Translation) Visiting FellowBerlin Institute of Health (Charité and Max Delbrück Center) | Berlin | Germany

Page 53: EVALUATION DIGITALER THERAPEUTIKA€¦ · R Salman (U Edinburgh) H Ewald (U Basel) KA Mc Cord (U Basel) M Briel (U Basel) C Pauli-Magnus (U Basel) HM Verkoijen (U Utrecht) U Dirnagl

Weiterführende Informationen

Fröbert et al. (TASTE trial). Thrombus aspiration during ST-segment elevation myocardial infarction. N Engl J Med. 2013

www.ncbi.nlm.nih.gov/pubmed/23991656

Nationwide registry based RCT (Scandinavia); 0% Loss-to-follow-up; >7000 pts; costs about 350‘000 EUR

Hemkens et al. Personalized Prescription Feedback Using Routinely Collected Data to Reduce Antibiotic Use in Primary Care:

A Randomized Clinical Trial. JAMA Intern Med. 2017 www.ncbi.nlm.nih.gov/pubmed/28027333

Nationwide admin/insurance data RCT (Switzerland); 2900 GPs, >10‘000‘000 consultations; 2 yrs; costs about 300‘000 USD

The Magic of Randomization versus the Myth of Real-World Evidence. Collins R, Bowman L, Landray M, Peto R.

N Engl J Med. 2020 www.ncbi.nlm.nih.gov/pubmed/32053307

„Nonrandomized observational analyses have been promoted as alternatives to randomized clinical trials. However,

randomization ensures balance between groups, whereas nonrandomized studies are often biased by between-group

differences. Efforts to reduce the cost and complexity of clinical trials are preferable to relying on observational studies.“

Using electronic health records for clinical trials: Where do we stand and where can we go?

Mc Cord KA, Hemkens LG. CMAJ. 2019 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4868623/pdf/188e158.pdf

How Routinely Collected Data for Randomized Trials Provide Long-term Randomized Real-World Evidence.

Hemkens LG. JAMA Netw Open. 2018 Dec 7;1(8):e186014

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2719124

Nonrandomized studies using causal-modeling may give different answers than RCTs: a meta-epidemiological study.

Ewald et al. J Clin Epidemiol 2020 https://www.ncbi.nlm.nih.gov/pubmed/31704350

Creating a Learning Health System through Rapid-Cycle, Randomized Testing Horwitz LI, Kuznetsova M, Jones SA.

N Engl J Med 2019; www.ncbi.nlm.nih.gov/pubmed/31532967 „Randomized tests of quality-improvement interventions were

embedded within an existing health care system. Quality and efficiency were improved by abandoning ineffective interventions

and continuing successful quality-improvement strategies.“